BlossomHill (BLSM) Director Carl L. Gordon Receives 23,904-Share Award

What Happened

• Carl L. Gordon, a director of BlossomHill Therapeutics, was granted a derivative award covering 23,904 shares on August 6, 2026. The award is reported as an acquisition (Form 4 code A) with a reported price of $0.00. This is an award/option-style grant rather than an open-market purchase or sale.

Key Details

• Transaction date: 2026-08-06; Filing date (Form 4): 2026-08-10 (appears to be timely).
• Transaction type/code: Award/Grant (A); derivative security shown.
• Shares/units: 23,904 shares awarded; reported price $0.00 (no cash paid at grant).
• Vesting: 1/36th of the shares subject to the option vest in equal monthly installments over a three-year period beginning August 6, 2026 (footnote F1).
• Transfer/beneficial interest: The filer is obligated to transfer any securities or economic benefit from these awards to OrbiMed Advisors LLC, which will ensure they are provided to OrbiMed Private Investments VIII, LP (footnote F2)—indicating the award is passed through to that investment vehicle.
• Shares owned after transaction: Not specified in the provided filing excerpt.

Context

• This filing documents an awarded/option-like grant (derivative). Such grants are typically compensation or incentive awards and do not reflect an immediate open-market purchase or sale. The vesting schedule means benefits accrue over time rather than all at once. The reported transfer arrangement indicates the economic benefit will flow to an investment fund (OrbiMed Private Investments VIII, LP) rather than the director retaining direct beneficial ownership.